title: HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.
abstract: OBJECTIVE
  The association between HER-2-positivity, and prognostic variables and survival have been addressed in many studies with still controversial results because of the small series analyzed.
  
  
  METHODS
  A series of 1928 primary breast carcinomas was analyzed for the prognostic potential of HER-2 overexpression.
  
  
  RESULTS
  In our series, HER-2-positivity was not associated with nodal status, unless the number of infiltrated nodes was considered, whereas it was strongly associated with large tumors (P < 10(-4)), grade III tumors (P < 10(-4)), lymphoid infiltration (P < 10(-4)), and absence of hormone receptor expression (P < 10(-4)). HER-2 overexpression was a strong prognostic indicator in N+ patients (P < 10(-7)), whereas its prognostic impact was weak and not statistically significant in the N- patients. Analysis of the hazard ratio of relapse in relation to time from surgery indicates that the poor prognosis associated with HER-2 positivity in N+ patients was found to be attributable to a peak of relapses in the first 3-4 years from surgery. Multivariate analysis of different prognostic factors in HER-2+ and HER-2- subsets indicated that grade is the most important factor followed by nodal status, lymphoid infiltration, and tumor size in HER-2-negative breast carcinomas, whereas nodal status was the most important prognostic factor, with tumor size showing only borderline significance, in the HER-2-positive group.
  
  
  CONCLUSIONS
  Together, the results indicate that HER-2-positive breast carcinomas represent a particular subset of tumors with peculiar clinical and pathological behaviors. Thus, conclusions drawn from clinical trials, which serve as the basis for clinical management of breast carcinomas, might not always be valid for this low-frequency subset.
authors.affiliation: Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. menard@istitutotumori.mi.it
authors.forename: Sylvie
authors.initials: S
authors.lastname: Ménard
authors.forename: Andrea
authors.initials: A
authors.lastname: Balsari
authors.forename: Patrizia
authors.initials: P
authors.lastname: Casalini
authors.forename: Elda
authors.initials: E
authors.lastname: Tagliabue
authors.forename: Manuela
authors.initials: M
authors.lastname: Campiglio
authors.forename: Rosaria
authors.initials: R
authors.lastname: Bufalino
authors.forename: Natale
authors.initials: N
authors.lastname: Cascinelli
mesh_terms: D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality*; D002277:Carcinoma / Q000378:metabolism* / Q000401:mortality*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015999:Multivariate Analysis; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D013997:Time Factors
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases